Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.71
NAS:CYTX's Cash-to-Debt is ranked lower than
82% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:CYTX: 0.71 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CYTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 2.67 Max: No Debt
Current: 0.71
Equity-to-Asset 0.32
NAS:CYTX's Equity-to-Asset is ranked lower than
78% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:CYTX: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CYTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.1  Med: 0.17 Max: 0.94
Current: 0.32
-1.1
0.94
Piotroski F-Score: 4
Altman Z-Score: -15.81
Beneish M-Score: -2.70
WACC vs ROIC
21.20%
-121.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -173.16
NAS:CYTX's Operating Margin % is ranked lower than
54% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. NAS:CYTX: -173.16 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CYTX' s Operating Margin % Range Over the Past 10 Years
Min: -3958.33  Med: -244.92 Max: -131.11
Current: -173.16
-3958.33
-131.11
Net Margin % -193.73
NAS:CYTX's Net Margin % is ranked lower than
57% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. NAS:CYTX: -193.73 )
Ranked among companies with meaningful Net Margin % only.
NAS:CYTX' s Net Margin % Range Over the Past 10 Years
Min: -3620.2  Med: -240.66 Max: -157.61
Current: -193.73
-3620.2
-157.61
ROE % -174.08
NAS:CYTX's ROE % is ranked lower than
88% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. NAS:CYTX: -174.08 )
Ranked among companies with meaningful ROE % only.
NAS:CYTX' s ROE % Range Over the Past 10 Years
Min: -596.71  Med: -339.9 Max: -174.08
Current: -174.08
-596.71
-174.08
ROA % -59.67
NAS:CYTX's ROA % is ranked lower than
65% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:CYTX: -59.67 )
Ranked among companies with meaningful ROA % only.
NAS:CYTX' s ROA % Range Over the Past 10 Years
Min: -127.5  Med: -64.74 Max: -49.06
Current: -59.67
-127.5
-49.06
ROC (Joel Greenblatt) % -1133.34
NAS:CYTX's ROC (Joel Greenblatt) % is ranked lower than
58% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:CYTX: -1133.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CYTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1697.26  Med: -1143.13 Max: -620.81
Current: -1133.34
-1697.26
-620.81
3-Year Revenue Growth Rate -37.50
NAS:CYTX's 3-Year Revenue Growth Rate is ranked lower than
77% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. NAS:CYTX: -37.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CYTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -14.25 Max: 88.4
Current: -37.5
0
88.4
3-Year EBITDA Growth Rate -39.10
NAS:CYTX's 3-Year EBITDA Growth Rate is ranked lower than
89% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAS:CYTX: -39.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CYTX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -40.3  Med: -16.3 Max: 37.5
Current: -39.1
-40.3
37.5
3-Year EPS without NRI Growth Rate -39.70
NAS:CYTX's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:CYTX: -39.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CYTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41.5  Med: -14 Max: 102.7
Current: -39.7
-41.5
102.7
GuruFocus has detected 2 Warning Signs with Cytori Therapeutics Inc $NAS:CYTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CYTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CYTX Guru Trades in

Q2 2015

CYTX Guru Trades in Q2 2015

George Soros 22,400 sh (New)
» More
Q3 2015

CYTX Guru Trades in Q3 2015

George Soros Sold Out
» More
Q4 2016

CYTX Guru Trades in Q4 2016

Jim Simons 10,091 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 339112    SIC: 3841
Compare:OTCPK:KBIO, OTCPK:NEWG, NAS:AZRX, NAS:CSBR, NAS:VKTX, NAS:ANTH, OTCPK:NWBO, OTCPK:GBLX, NAS:APVO, NAS:HSGX, NAS:APOP, NAS:ZSAN, OTCPK:DMYDF, AMEX:IBIO, AMEX:BPMX, OTCPK:RGRX, NAS:MRNS, NAS:CLBS, NAS:TPIV, NAS:XBIO » details
Traded in other countries:XMPB.Germany,
Cytori Therapeutics Inc is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns.

Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
PB Ratio 2.54
CYTX's PB Ratio is ranked higher than
66% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. CYTX: 2.54 )
Ranked among companies with meaningful PB Ratio only.
CYTX' s PB Ratio Range Over the Past 10 Years
Min: 2.12  Med: 30.48 Max: 797.32
Current: 2.54
2.12
797.32
PS Ratio 2.25
CYTX's PS Ratio is ranked higher than
89% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. CYTX: 2.25 )
Ranked among companies with meaningful PS Ratio only.
CYTX' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 11.2 Max: 42.53
Current: 2.25
1.56
42.53
EV-to-EBIT -1.95
CYTX's EV-to-EBIT is ranked lower than
99.99% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. CYTX: -1.95 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -16  Med: -4.9 Max: 63
Current: -1.95
-16
63
EV-to-EBITDA -2.07
CYTX's EV-to-EBITDA is ranked lower than
99.99% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. CYTX: -2.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.5  Med: -5.1 Max: 31
Current: -2.07
-17.5
31
Current Ratio 1.50
CYTX's Current Ratio is ranked lower than
75% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CYTX: 1.50 )
Ranked among companies with meaningful Current Ratio only.
CYTX' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.48 Max: 32.68
Current: 1.5
1.36
32.68
Quick Ratio 1.20
CYTX's Quick Ratio is ranked lower than
74% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CYTX: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
CYTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 2.11 Max: 31.14
Current: 1.2
1.06
31.14
Days Inventory 563.70
CYTX's Days Inventory is ranked lower than
98% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. CYTX: 563.70 )
Ranked among companies with meaningful Days Inventory only.
CYTX' s Days Inventory Range Over the Past 10 Years
Min: 70.92  Med: 307.36 Max: 563.7
Current: 563.7
70.92
563.7
Days Sales Outstanding 39.84
CYTX's Days Sales Outstanding is ranked higher than
76% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. CYTX: 39.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.15  Med: 64.69 Max: 124.26
Current: 39.84
4.15
124.26
Days Payable 179.07
CYTX's Days Payable is ranked lower than
99.99% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CYTX: 179.07 )
Ranked among companies with meaningful Days Payable only.
CYTX' s Days Payable Range Over the Past 10 Years
Min: 25.87  Med: 116.71 Max: 414.3
Current: 179.07
25.87
414.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.80
CYTX's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CYTX: -53.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67  Med: -22.8 Max: 2.7
Current: -53.8
-67
2.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.20
CYTX's Price-to-Median-PS-Value is ranked higher than
95% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CYTX: 0.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.13 Max: 1.93
Current: 0.2
0.19
1.93
Earnings Yield (Greenblatt) % -51.28
CYTX's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. CYTX: -51.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -51.28  Med: 2.2 Max: 2.8
Current: -51.28
-51.28
2.8

More Statistics

Revenue (TTM) (Mil) $11.38
EPS (TTM) $ -1.32
Beta3.01
Short Percentage of Float1.75%
52-Week Range $1.36 - 5.44
Shares Outstanding (Mil)23.57

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 14 25 77
EPS ($) -0.96 -0.48 1.63
EPS without NRI ($) -0.96 -0.48 1.63
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
5-year lows: Fuel Systems Solutions Inc, Dawson Geophysical Co, Forest Oil Corp, and Cytori Therapeu Sep 08 2014 
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 6,600 Shares May 20 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 3,250 Shares May 19 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 7,000 Shares May 18 2009 

More From Other Websites
ETFs with exposure to Cytori Therapeutics, Inc. : March 30, 2017 Mar 29 2017
Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Mar 28 2017
Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: 2016 By the Numbers : March 28, 2017 Mar 28 2017
CYTORI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 24 2017
Cytori reports 4Q loss Mar 23 2017
Cytori reports 4Q loss Mar 23 2017
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 23 2017
Cytori Reports Fourth Quarter and Full Year 2016 Business and Financial Results Mar 23 2017
Cytori to Webcast Fourth Quarter Financial Results on March 23rd Mar 17 2017
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 03 2017
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion... Feb 15 2017
Cytori Completes Acquisition of Azaya Therapeutics Assets, Initiates Nanomedicine Program Feb 15 2017
Cytori Provides Latest Corporate Update at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 14 2017
Cytori Wins Small Business Status, Stock Spikes Feb 07 2017
Cytori Receives U.S. Small Business Designation - Substantially Reduces 2017 FDA Filing Fees Feb 06 2017
Cytori To Buy Cancer Drug Group Azaya for $170M Jan 20 2017
San Diego company to buy stalled San Antonio-based cancer drug developer Jan 19 2017
Cytori Therapeutics stock surges 7.9% on agreement to buy assets from Azaya Therapeutics Jan 19 2017
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 19 2017
Cytori to Acquire Proprietary Nanoparticle Development Platform to Enhance Regenerative Medicine... Jan 19 2017
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 10 2017
Cytori to Expand Scleroderma Focus to Broader Hand Therapy Franchise Under the Habeo™ Cell Therapy... Jan 10 2017
Cytori Therapeutics to Provide Corporate Update at 2017 Biotech Showcase™ Jan 06 2017
Cytori Therapeutics to Provide Corporate Update at 2017 Biotech Showcase™ Jan 06 2017
Cytori Announces Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital... Dec 29 2016
Ronald Martell to Join Cytori Therapeutics’ Board of Directors Dec 28 2016
Cytori Cell Therapy™ Leads to Improved Corneal Wound Healing and Reduced Scarring Nov 21 2016
Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma Nov 14 2016
Cytori Reports Third Quarter 2016 Business and Financial Results Nov 09 2016
Cytori to Present Data in Two Distinct Models of Impaired Wound Healing Nov 04 2016
Cytori to Webcast Third Quarter Financial Results on November 9 Oct 26 2016
Cytori Publication on Cytori Cell Therapy for Combined Radiation and Thermal Injury Oct 24 2016
Cytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss Sep 26 2016
BARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial Sep 19 2016
Case Report Illustrates the Potential Value Cytori Cell Therapy in Treating Chronic Effects of... Sep 12 2016
Cytori to Present in Investor Events in September 2016 Sep 01 2016
Cytori Therapeutics Announced Inducement Grant for New Employee Aug 05 2016
Cytori Reports Second Quarter 2016 Business and Financial Results Aug 04 2016
What Do All These Investigator-Initiated Studies Mean to Cytori? Jul 25 2016
Cytori to Webcast Second Quarter Financial Results on August 4 Jul 22 2016
Cytori ATHENA Trial for Chronic Ischemic Cardiovascular Disease Jun 28 2016
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan Jun 27 2016
Cytori Cell Therapy Receives Limited Approval for Osteoarthritis in Japan Jun 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)